A5013494474- Sarcoma Diagnosis and Treatment
- Magnetic confinement fusion research
- Fusion materials and technologies
- Superconducting Materials and Applications
- Bone Tumor Diagnosis and Treatments
- Tumors and Oncological Cases
- Ionosphere and magnetosphere dynamics
- Testicular diseases and treatments
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Particle accelerators and beam dynamics
- Surgical site infection prevention
- Plasma Diagnostics and Applications
- Advanced Data Storage Technologies
- Childhood Cancer Survivors' Quality of Life
- Laser-Plasma Interactions and Diagnostics
- Distributed and Parallel Computing Systems
- Nuclear Physics and Applications
- Nuclear reactor physics and engineering
- Chemotherapy-induced organ toxicity mitigation
- Renal and related cancers
- Cancer-related molecular mechanisms research
- Acute Lymphoblastic Leukemia research
Lawrence Livermore National Laboratory
2015-2024
University of Oklahoma Health Sciences Center
2014-2023
Seattle Children's Hospital
2004-2018
Children's Oncology Group
2004-2018
Janssen (Belgium)
2018
Boehringer Ingelheim (Australia)
2018
Elekta (Switzerland)
2018
AstraZeneca (Poland)
2018
GlaxoSmithKline (India)
2018
Pfizer (United States)
2018
The motivation for lithium battery development and a discussion of ion conducting polymers as separators begin this review, which includes short history polymer electrolyte research, summary the major parameters that determine transport in matrices, consequences solid development. Two strategies application batteries are identified: One is highly conductive materials via crosslinking mobile chains to form networks, then swollen by salt solutions (“gel electrolytes”). other construction...
To identify risk factors associated with outcomes in children metastatic rhabdomyosarcoma (RMS) treated on the fourth Intergroup Rhabdomyosarcoma Study (IRS-IV).Patients RMS were one of two regimens that incorporated a window either ifosfamide and etoposide (IE) vincristine, dactinomycin, cyclophosphamide (VAC) or melphalan (VM) VAC. end points failure-free survival (FFS) overall (OS). Clinical including age, histology, sites primary disease, number disease correlated those points.One...
To identify risk factors associated with outcome in children metastatic rhabdomyosarcoma a large cohort of patientsPooled data were obtained from 788 patients treated nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site primary, site(s) number sites disease, correlated event-free survival (EFS) overall (OS).Seven hundred eighty-eight eligible for analysis. The 3-year OS EFS 34% (SE, 1.7) 27% 1.6), respectively. By univariate...
Purpose The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy. Patients Methods We evaluated patient disease characteristics their ability to predict patients with nonmetastatic RMS UDS treated on Intergroup Rhabdomyosarcoma Study (IRS) -III (1984 1991) IRS-IV (1991 1997). Results estimated 5-year failure-free survival (FFS) rate was 90% embryonal (ERMS) stage 1, group I IIa; 2,...
To determine the relationship between state of actin polymerization in neutrophils and formyl-methionyl-leucyl-phenylalanine (fMLP)-induced changes locomotive behavior neutrophils, mean rate locomotion (mROL), percent G-actin, relative F-actin content were determined. The mROL was quantified by analysis individual cells; percentage total as G-actin measured DNase I inhibition; determined fluorescence-activated cell sorter (FACS) nitrobenzoxadiazol (NBD)-phallacidin-stained neutrophils....
Purpose The purpose of this study was to compare the outcome patients with intermediate-risk rhabdomyosarcoma (RMS) treated standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy that alternating vincristine, topotecan, cyclophosphamide (VAC/VTC). Patients Methods were randomly assigned 39 weeks versus VAC/VTC; local therapy began after week 12. parameningeal RMS intracranial extension (PME) immediate x-ray therapy. primary end point failure-free survival (FFS). designed...
Rhabdomyosarcoma (RMS) in children occurs as two major histological subtypes, embryonal (ERMS) and alveolar (ARMS). ERMS is associated with an 11p15.5 loss of heterozygosity (LOH) may be confused nonmyogenic, non-RMS soft tissue sarcomas. ARMS expresses the product a genomic translocation that fuses FOXO1 (FKHR) either PAX3 or PAX7 (P-F); however, at least 25% cases lack these translocations. Here, we describe genomic-based classification scheme derived from combined gene expression...
Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years embryonal RMS, have an estimated long-term event-free survival (EFS) of less 20%. The main goal this study was to improve outcome patients RMS by dose intensification interval compression, use the most active agents determined in phase II window studies, and irinotecan as a radiation sensitizer.Patients received 54 weeks therapy: blocks therapy vincristine/irinotecan (weeks 1 6, 20 25, 47 52), compression...
AbstractAbstractPhysics elements and advances crucial for the development of axisymmetric magnetohydrodynamic equilibrium reconstruction to support plasma operation data analysis in DIII-D tokamak are reviewed. A response function formalism a Picard linearization scheme used efficiently combine fitting iterations search optimum solution vector. Algorithms incorporate internal current pressure profile measurements, topological constraints, toroidal rotation into described. Choice basis...
Patients with localized, grossly resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival (FFS) rates of 83% and overall 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV. IRSG D9602 protocol (1997 to 2004) objectives were decrease toxicity in similar patients by reducing radiotherapy (RT) doses eliminating cyclophosphamide for the lowest-risk patients.Subgroup A (lowest risk, ERMS, stage 1 group I/IIA, III orbit, 2 I)...
Immunohistochemistry remains the current ancillary method of choice in pathologic evaluation small blue round-cell tumors. In at least 20% cases rhabdomyosarcoma (RMS), it is considered an essential factor final and/or differential diagnosis malignancy. Newer immunostains (antimyogenin, MyoD1) generated against intranuclear myogenic transcription factors offer pathologists best hope for improving sensitivity and specificity RMS diagnosis. A large series (956) were studied consecutively from...
Purpose To estimate the antitumor activity and toxicity of irinotecan alone in combination with vincristine when administered as window therapy standard chemotherapy pediatric patients newly diagnosed metastatic rhabdomyosarcoma. Patients Methods Nineteen younger than age 21 years rhabdomyosarcoma or undifferentiated sarcoma received two cycles (20 mg/m 2 daily for 5 days, repeated weeks) 50 1.5 (weeks 0, 1, 3, 4) weeks). who achieved a partial response (PR) complete (CR) these agents...
Fifty-two previously untreated patients with localized Ewing's sarcoma of bone were treated nonintensive chemotherapy in combination surgery or radiation therapy (RT). RT was delivered to limited volumes a dose dependent on the initial response induction (30 35 Gy v 50 55 Gy). Fifty 52 achieved complete partial responses chemotherapy, one nonresponding patient rendered free tumor surgery. evaluable for local control and overall protocol therapy. Seventeen relapses have occurred; three...
We assessed two antibiotic regimens — vancomycin, ticarcillin, and amikacin, as compared with a vancomycin placebo, ticarcillin–clavulanate, amikacin initial empirical therapy for febrile, neutropenic children cancer. In randomized, double-blind clinical trial, the planned 10-day treatment was unsuccessful in 15 percent of group (n = 53), 38 receiving ticarcillin–clavulanate 48) (P 0.010). Of 10 episodes breakthrough bacteremia, 9 (1 fatal) occurred patients treated 0.006). Each microbial...
Purpose Intermediate-risk rhabdomyosarcoma (RMS) includes patients with either nonmetastatic, unresected embryonal RMS (ERMS) an unfavorable primary site or nonmetastatic alveolar (ARMS). The aim of this study was to improve the outcome intermediate-risk by substituting vincristine and irinotecan (VI) for half vincristine, dactinomycin, cyclophosphamide (VAC) courses. All received a lower dose earlier radiation therapy than in previous trials. Patients Methods were randomly assigned at entry...
Purpose Intergroup Rhabdomyosarcoma Study Group (IRSG) studies III and IV showed improved failure-free survival (FFS) rates with vincristine, dactinomycin, cyclophosphamide (VAC; total cumulative dose, 26.4 g/m 2 ) compared vincristine dactinomycin (VA) for patients subset-one low-risk embryonal rhabdomyosarcoma (ERMS; stage 1/2 group I/II ERMS or 1 orbit ERMS). The objective of Children's Oncology ARST0331 was to reduce the length therapy without compromising FFS this subset by using VA in...
Previous studies of the prognostic importance FOXO1 fusion status in patients with rhabdomyosarcoma (RMS) have had conflicting results. We re-examined risk stratification by adding to traditional clinical factors children localized or metastatic RMS.Data from six COG trials (D9602, D9802, D9803, ARST0331, ARTS0431, ARST0531; two each for low-, intermediate- and high-risk patients) accruing previously untreated RMS 1997 2013 yielded 1727 evaluable patients. Survival tree regression event-free...
Abstract Background Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non‐cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety efficacy of in prospective phase II study within Children's Oncology Group. Procedures Eligible patients were <19 years age who had measurable DT was recurrent or not amenable surgery radiation....
Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal (ERMS) has historically been of prognostic and therapeutic importance. However, classification complicated by shifting histologic criteria required for an ARMS diagnosis. Children's Oncology Group (COG) studies after IRS-IV, which included the height this diagnostic shift, showed both increased number increase in proportion fusion-negative ARMS. Following standardization re-review cases enrolled during era, analysis low-risk...
The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus for additional investigation in rhabdomyosarcoma (RMS) when administered combination with cytotoxic chemotherapy patients RMS first relapse unfavorable prognosis.Patients were randomly assigned receive on day 1 days 1, 8, and 15 each 21-day treatment cycle, together vinorelbine cyclophosphamide a maximum 12 cycles. Local tumor control surgery and/or radiation therapy permitted after 6 weeks treatment. end...